Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.

@article{Casanova2006CelecoxibIA,
  title={Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas.},
  author={I. Berenguer Valles Casanova and Matilde Parre{\~n}o and Lourdes Farr{\'e} and S{\'i}lvia Guerrero and Mar{\'i}a Virtudes C{\'e}spedes and Miguel Angel Pav{\'o}n and Francesc Josep Sancho and Eugenio Marcuello and Manuel Tr{\'i}as and Ram{\'o}n Mangues},
  journal={International journal of cancer},
  year={2006},
  volume={118 10},
  pages={2381-9}
}
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is effective as chemopreventive against colon cancer and it is the only nonsteoroidal antiinflammatory drug approved by the FDA for adjuvant therapy in patients with familial adenomatous polyposis. It is also being evaluated, within Phase II and III clinical trials, in combination with standard chemotherapy to treat sporadic colorectal cancer. Nevertheless, its antitumor mechanism of action is still not fully understood. In this study… CONTINUE READING
Highly Cited
This paper has 29 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…